US equities |
NVDA $240.75 ▲+0.77% SPCX $173.70 ▲+1.53% MU $1,065.86 ▲+0.18% MRVL $286.83 ▲+5.74% AMD $656.12 ▲+3.86% SNDK $1,674.32 ▼-1.75% AVGO $378.28 ▲+4.35% INTC $113.21 ▼-2.56%
FinancialContent

Foghorn Therapeutics Inc. - Common Stock (NQ:FHTX)

1.940 -0.060 (-3.00%)
Delayed Quote Updated: 12:31 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Foghorn Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
This Worthington Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Foghorn Therapeutics (FHTX) Stock Is Trading Lower ↗
Foghorn Therapeutics shares are trading lower by 20.2% during Monday's session. The company announced it will discontinue independent development of its FHD-286 program. 
Via Benzinga
News headline image
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in the BMO Oncology Summit
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >